These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 1587057)

  • 1. Bayesian parameter estimation and population pharmacokinetics.
    Thomson AH; Whiting B
    Clin Pharmacokinet; 1992 Jun; 22(6):447-67. PubMed ID: 1587057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].
    Marquet P
    Acta Clin Belg; 1999; 53 Suppl 1():2-12. PubMed ID: 10216973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies.
    el Desoky E; Meinshausen J; Bühl K; Engel G; Harings-Kaim A; Drewelow B; Klotz U
    Ther Drug Monit; 1993 Aug; 15(4):281-8. PubMed ID: 8236362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
    Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
    J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
    Carlsson KC; Hoem NO; Glauser T; Vinks AA
    Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics II: estimation methods.
    Ette EI; Williams PJ
    Ann Pharmacother; 2004 Nov; 38(11):1907-15. PubMed ID: 15367729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Is therapeutic drug monitoring (TDM) in paediatric patients necessary?].
    Prokopczyk J; Piekarczyk A; Kaminska E
    Med Wieku Rozwoj; 2001; 5(2):149-55. PubMed ID: 11679679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian estimation of a cancer population by capture-recapture with individual capture heterogeneity and small sample.
    Bailly L; Daurès JP; Dunais B; Pradier C
    BMC Med Res Methodol; 2015 Apr; 15():39. PubMed ID: 25902941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contribution of computers to pharmacokinetics, Bayesian approach and population pharmacokinetics].
    Hecquet B
    Bull Cancer; 1995 Dec; 82 Suppl 5():607s-611s. PubMed ID: 8680074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality, origins and limitations of common therapeutic drug reference intervals.
    McCudden CR
    Diagnosis (Berl); 2018 Jun; 5(2):47-61. PubMed ID: 29794249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using population-based serum drug concentration cutoff values to predict toxicity: test performance and limitations compared with Bayesian interpretation.
    Schumacher GE; Barr JT
    Clin Pharm; 1990 Oct; 9(10):788-96. PubMed ID: 2242660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring and pharmacokinetic dose prediction methods.
    Oellerich M
    Wien Klin Wochenschr Suppl; 1992; 191():12-5. PubMed ID: 1509745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.
    Gomeni R; Pineau G; Mentré F
    Anticancer Res; 1994; 14(6A):2321-6. PubMed ID: 7825966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian and threshold probabilities in therapeutic drug monitoring: when can serum drug concentrations alter clinical decisions?
    Schumacher GE; Barr JT
    Am J Hosp Pharm; 1994 Feb; 51(3):321-7. PubMed ID: 8160684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [TDM (therapeutic drug monitoring) for dosing theophylline].
    Ueda W
    Masui; 1991 Oct; 40(10):1536-41. PubMed ID: 1766103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.
    Merlé Y; Mentré F
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):101-25. PubMed ID: 8576840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.
    Bondareva IB; Jelliffe RW; Gusev EI; Guekht AB; Melikyan EG; Belousov YB
    J Clin Pharm Ther; 2006 Jun; 31(3):211-21. PubMed ID: 16789986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Can we use a Bayesian method to build a pharmacokinetic population in two steps?].
    Cabelguenne D; Bleyzac N; Pivot C; Maire P
    Therapie; 2000; 55(2):277-82. PubMed ID: 10967700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis.
    Mahmood I; Miller R
    Int J Clin Pharmacol Ther; 1999 Sep; 37(9):439-45. PubMed ID: 10507242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.